Title: Etanercept: effectiveness and safety data of a retrospective study
Abstract: Journal of the European Academy of Dermatology and VenereologyVolume 25, Issue 9 p. 1113-1115 LETTERS TO THE EDITOR Etanercept: effectiveness and safety data of a retrospective study C. Antoniou, C. Antoniou Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorT. Vergou, Corresponding Author T. Vergou T. Vergou. E-mail: [email protected]Search for more papers by this authorC. Dessinioti, C. Dessinioti Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorA.J. Stratigos, A.J. Stratigos Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorG. Avgerinou, G. Avgerinou Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorP. Stavropoulos, P. Stavropoulos Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorA. Katsambas, A. Katsambas Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this author C. Antoniou, C. Antoniou Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorT. Vergou, Corresponding Author T. Vergou T. Vergou. E-mail: [email protected]Search for more papers by this authorC. Dessinioti, C. Dessinioti Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorA.J. Stratigos, A.J. Stratigos Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorG. Avgerinou, G. Avgerinou Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorP. Stavropoulos, P. Stavropoulos Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this authorA. Katsambas, A. Katsambas Psoriasis Unit, Department of Dermatology, University of Athens, Andreas Sygros Hospital, Athens, GreeceSearch for more papers by this author First published: 04 August 2011 https://doi.org/10.1111/j.1468-3083.2010.03820.xCitations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88(5): 1242–1247. 2 Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719–726. 3 Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 2007; 17(6): 546–547. 4 Driessen RJB, Boezeman JB, Van de Kerkhof PCM, De Jong EM. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670–675. 5 Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–2022. 6 Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304–1312. 7 Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue and depression in psoriasis: double-blind placebo controlled randomized phase III trial. Lancet 2006; 367: 29–35. Citing Literature Volume25, Issue9September 2011Pages 1113-1115 ReferencesRelatedInformation
Publication Year: 2011
Publication Date: 2011-08-04
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 10
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot